Sanofi's Toujeo(R) Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus(R) at All Levels of HbA1c control

PR65727

PARIS, Sep. 13 / PRNewswire-=KYODO JBN / --

  - Benefits on adherence and HbA1c to be validated in a real-world setting -

    Sanofi [http://www.sanofi.com ] announced today that adults with type 2

diabetes treated with Toujeo(R) (insulin glargine 300 Units/mL) experienced a

consistently lower rate of confirmed or severe hypoglycemia both at night and

at any time of the day compared with those treated with Lantus(R) (insulin

glargine 100 Units/mL), at all levels of HbA1c (average blood glucose over the

previous three months) achieved at month 6. The results of this new

patient-level meta-analysis from the EDITION 1, 2 and 3 Phase 3 clinical trials

in patients with type 2 diabetes were presented at the 52nd Annual Meeting of

the European Association for the Study of Diabetes (EASD) in Munich, Germany.

    "For people with diabetes, it is vital to achieve good glycemic control in

order to minimize the risk of microvascular complications. Risk of hypoglycemia

can be an important factor in the person as well as their treating physician's

attitude towards treatment of their diabetes, and can lead to improved

adherence and reduced glycemic control in real-world conditions," said Pratik

Choudhary, Senior Lecturer and Consultant in Diabetes, Kings College London, UK

and lead author of the presentation. "These results show that in more than

2,000 patients that Toujeo could enable adults with type 2 diabetes to achieve

equivalent glycemic control with less hypoglycemia vs. Lantus. We look forward

to the validation of these important findings in real-world settings."

    In addition, the first clinical evidence in a real life setting to reflect

the possibility of achieving glycemic control with fewer hypoglycemic events

was presented at the American Diabetes Association (ADA) 76th Scientific

Sessions. Those data were drawn from existing patient-level information (from

the Predictive Health Intelligence Environment database) on patients switching

to Toujeo from other basal insulins under real-life conditions. The results

demonstrated that patients treated with Toujeo experienced a mean estimated

reduction in HbA1c of 0.64% (p＜0.0001) after 6 months of treatment, while the

occurrence of hypoglycemia was 6.0% at baseline and 5.1% at follow-up.

    "These encouraging meta-analysis findings, in combination with preliminary

patient-level data from a real-life setting, provide useful information about

Toujeo's potential to help people with diabetes achieve better glycemic control

without additional risk of hypoglycemia," said Riccardo Perfetti, Head of

Global Diabetes Medical Team, Sanofi. "We are currently conducting a broad

real-world clinical program to confirm these findings."

    Sanofi is conducting three large, randomized clinical trials - ACHIEVE,

REACH and REGAIN CONTROL - evaluating in real-life conditions the effect of

Toujeo in people with type 2 diabetes. These trials will provide an important

evaluation of the effectiveness of Toujeo's disease-management strategy, that

could be particularly relevant to healthcare professionals, diabetes educators

and payers.

    About EASD abstract

    The meta-analysis was performed on patient-level data from the EDITION 1, 2

and 3 phase 3 clinical trials (n=2,103). Annualized rate of confirmed (less

than or equal to3.9 mmol/L or less than or equal to70.2 mg/dL) or severe

hypoglycemia rate (events per participant-year) was correlated with HbA1c data

at month 6 for each patient, using a negative binomial regression model. There

was no overlap between the curves for Toujeo(R) (insulin glargine 300 Units/mL)

and Lantus(R) (insulin glargine 100 Units/mL), demonstrating that the

hypoglycemia rate was lower with Toujeo(R) than with Lantus(R) at all levels of

HbA1c.

    The presentation is titled: "Hypoglycaemia as a function of HbA1c in type 2

diabetes (T2DM): insulin glargine 300 U/ml in a patient-level meta-analysis of

EDITION 1, 2 and 3" (Choudhary P, et al. Oral presentation #10, European

Association for the Study of Diabetes (EASD) 52nd Annual Meeting, Munich,

Germany, September 13, 2016).

    About patient-level information from the PHIE database

    Adults with type 2 diabetes who had used other basal insulins within the 6

months prior to Toujeo initiation (one or more prescription orders of Toujeo(R)

between March 2015 and December 2015) were identified. The PHIE records of

those identified (n=881) were assessed for HbA1c and incidence of confirmed

(less than or equal to3.9 mmol/L or less than or equal to70.2 mg/dL) or severe

hypoglycemia up to 6 months prior to and up to 6 months after initiation.

    Among the subpopulation of patients (n=267) with HbA1c measured at baseline

and during follow-up (0-6 months), mean HbA1c was 8.97% at baseline and 8.33%

at follow-up. For the subpopulation of patients (n=449) with occurrence of

hypoglycemia reported at baseline and during follow-up (0-3 months), this was

6.0% at baseline and 5.1% at follow-up.

    The poster is titled "Real-World Assessment of Patient Characteristics and

Clinical Outcomes of Early Users of the New Insulin Glargine 300U/mL" (Ye F, et

al. Poster presentation 943-P, New Orleans, LA, U.S., Saturday, June 11, 2016).

    About ACHIEVE, REACH and REGAIN CONTROL

    The ACHIEVE CONTROL study will evaluate the effect of Toujeo(R) versus

other basal insulins in a real-life setting on achieving individualized

glycemic targets without hypoglycemia at any time of day in 3,270 uncontrolled

insulin-naive people in the U.S. with type 2 diabetes.

    The REACH CONTROL will follow 920 insulin-naive people with type 2 diabetes

in Europe, comparing HbA1c change with Toujeo(R) versus other basal insulins,

alongside incidence of hypoglycemia, change in body weight, and measures of

persistence with treatment and need for treatment intensification in a

real-life setting.

    The REGAIN CONTROL study will compare HbA1c reduction, incidence of

hypoglycemia, change in body weight and persistence with treatment on Toujeo(R)

versus other basal insulins in 800 people with type 2 diabetes in Europe, who

are currently uncontrolled on basal insulin in a real-life setting. In addition

to clinical measures, the studies will also collect patient feedback on

treatment satisfaction and their experience of hypoglycemia, along with

healthcare resource utilization.

    About Toujeo(R)

    Toujeo(R) is a once-daily basal insulin based on a broadly-used molecule

(insulin glargine). Toujeo has been approved by the U.S. Food and Drug

Administration (FDA), the European Commission, Health Canada, the Therapeutic

Goods Administration in Australia, and the MHLW in Japan (where its approved

brand name is Lantus(R) XR), and is under review by other regulatory

authorities around the world.

    About Sanofi

    Sanofi, a global healthcare leader, discovers, develops and distributes

therapeutic solutions focused on patients' needs. Sanofi is organized into five

global business units: Diabetes and Cardiovascular, General Medicines and

Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed

in Paris (EURONEXT: SAN

[http://en.sanofi.com/investors/share/stock_chart/stock_chart.aspx ]) and in

New York (NYSE: SNY

[http://en.sanofi.com/investors/share/stock_chart/stock_chart.aspx ]).

    Sanofi Forward-Looking Statements

    This press release contains forward-looking statements as defined in the

Private Securities Litigation Reform Act of 1995, as amended. Forward-looking

statements are statements that are not historical facts. These statements

include projections and estimates and their underlying assumptions, statements

regarding plans, objectives, intentions and expectations with respect to future

financial results, events, operations, services, product development and

potential, and statements regarding future performance. Forward-looking

statements are generally identified by the words "expects", "anticipates",

"believes", "intends", "estimates", "plans" and similar expressions. Although

Sanofi's management believes that the expectations reflected in such

forward-looking statements are reasonable, investors are cautioned that

forward-looking information and statements are subject to various risks and

uncertainties, many of which are difficult to predict and generally beyond the

control of Sanofi, that could cause actual results and developments to differ

materially from those expressed in, or implied or projected by, the

forward-looking information and statements. These risks and uncertainties

include among other things, the uncertainties inherent in research and

development, future clinical data and analysis, including post marketing,

decisions by regulatory authorities, such as the FDA or the EMA, regarding

whether and when to approve any drug, device or biological application that may

be filed for any such product candidates as well as their decisions regarding

labelling and other matters that could affect the availability or commercial

potential of such product candidates, the absence of guarantee that the product

candidates if approved will be commercially successful, the future approval and

commercial success of therapeutic alternatives, Sanofi's ability to benefit

from external growth opportunities and/or obtain regulatory clearances, risk

associated with intellectual property and any related pending or future

litigation and the ultimate outcome of such litigation, trends in exchange

rates and prevailing interest rates, the impact of cost containment initiatives

and subsequent changes thereto, the average number of shares outstanding as

well as those discussed or identified in the public filings with the SEC and

the AMF made by Sanofi, including those listed under "Risk Factors" and

"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual

report on Form 20-F for the year ended December 31, 2015. Other than as

required by applicable law, Sanofi does not undertake any obligation to update

or revise any forward-looking information or statements.

    Source: Sanofi